Anuh Pharma has released its financial results for the second quarter, showcasing a mixed performance with revenue growth but a decline in profitability.

Revenue Growth

The pharmaceutical company reported a revenue increase to ₹1.86 billion for the quarter, up from ₹1.65 billion in the same period last year, marking a year-over-year growth of 12.7%.

Profit Decline

Despite the revenue growth, Anuh Pharma experienced a significant drop in net profit:

The company's profitability metrics show a substantial decline, with net profit nearly halving compared to the same quarter in the previous fiscal year.

Half-Year Performance

For the half-year ended September 30, Anuh Pharma's financial highlights include:

Operational Highlights

• The company's cost of materials consumed increased to ₹2,554.15 crore in the current half-year, up from ₹2,067.07 crore in the same period last year.
• Employee benefits expense rose to ₹130.43 crore from ₹106.57 crore year-over-year.
• Other expenses increased to ₹399.91 crore from ₹353.23 crore in the previous year's first half.

Balance Sheet Position

As of September 30, Anuh Pharma's balance sheet shows:

• Total assets of ₹5,086.71 crore, a slight increase from ₹5,066.28 crore as of March 31.
• Current assets, including inventories and trade receivables, remained stable at ₹3,788.58 crore compared to ₹3,785.77 crore at the end of the previous fiscal year.
• The company's equity share capital doubled to ₹501.12 crore from ₹250.56 crore, due to the issuance of bonus shares in a 1:1 ratio during the quarter.

Conclusion

While Anuh Pharma is experiencing growth in its top line, it faces challenges in maintaining profitability. The increased costs, particularly in materials and other expenses, appear to be putting pressure on the company's margins. The company's ability to address these challenges while continuing to grow its revenue will be crucial in the coming periods.

Anuh Pharma Limited , a prominent player in the pharmaceutical industry, held its 65th Annual General Meeting (AGM) on August 22, 2025, marking a significant milestone in the company's governance and strategic direction. The shareholders approved several key appointments and reappointments, reinforcing the company's leadership structure and compliance mechanisms.

Leadership Continuity and Experience

The AGM saw the reappointment of two Non-Executive Non-Independent Directors, Mr. Bharat Nemchand Shah and Mr. Gaurav Satish Shah. Mr. Bharat Shah brings a wealth of experience to the board with five decades in the pharmaceutical industry, while Mr. Gaurav Shah contributes 20 years of industry expertise, backed by a Bachelor's degree in Engineering from the USA and a Diploma in Family Managed Business Administration.

Joint Managing Directors Reappointed

In a move that ensures leadership stability, the shareholders approved the reappointment of Mr. Ritesh Shah and Mr. Vivek Shah as Joint Managing Directors for a five-year term from January 8, 2026, to January 7, 2031. Mr. Ritesh Shah, with 21 years of pharmaceutical experience, specializes in marketing, finance, business strategy, and sourcing. Mr. Vivek Shah, bringing over 15 years of experience, focuses on operations, R&D, and regulatory affairs.

Strengthening Audit and Compliance

The AGM also addressed key audit appointments:

1. Mr. Ankit Kishor Chande was reappointed as Cost Auditor for the financial year ending March 2026. With over 12 years of experience across 17 industries, Chande brings valuable expertise to Anuh Pharma's cost management processes.

2. M/s. GHV & Co., Practicing Company Secretaries, secured a five-year appointment as Secretarial Auditor from FY 2025-26 to FY 2029-30. The firm's extensive experience in secretarial compliance and corporate governance will support Anuh Pharma's regulatory adherence.

Shareholder Approval and Voting Results

The scrutinizer's report revealed overwhelming shareholder support for all resolutions presented at the AGM. Key appointments and reappointments received over 99.99% votes in favor, demonstrating strong shareholder confidence in the company's leadership and governance choices.

Dividend Declaration

In a positive move for shareholders, the AGM approved a dividend of Rs. 1.50 per equity share of face value Rs. 5 for the Financial Year 2024-25, reflecting the company's commitment to delivering value to its investors.

Anuh Pharma's 65th AGM decisions reflect a balance between continuity and compliance, positioning the company for sustained growth in the dynamic pharmaceutical sector. The reappointment of experienced leaders and the engagement of specialized auditors underscore the company's focus on strong governance and strategic direction.